Literature DB >> 20941431

Microfluidic labeling of biomolecules with radiometals for use in nuclear medicine.

Tobias D Wheeler1, Dexing Zeng, Amit V Desai, Birce Önal, David E Reichert, Paul J A Kenis.   

Abstract

Radiometal-based radiopharmaceuticals, used as imaging and therapeutic agents in nuclear medicine, consist of a radiometal that is bound to a targeting biomolecule (BM) using a bifunctional chelator (BFC). Conventional, macroscale radiolabeling methods use an excess of the BFC-BM conjugate (ligand) to achieve high radiolabeling yields. Subsequently, to achieve maximal specific activity (minimal amount of unlabeled ligand), extensive chromatographic purification is required to remove unlabeled ligand, often resulting in longer synthesis times and loss of imaging sensitivity due to radioactive decay. Here we describe a microreactor that overcomes the above issues through integration of efficient mixing and heating strategies while working with small volumes of concentrated reagents. As a model reaction, we radiolabel 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) conjugated to the peptide cyclo(Arg-Gly-Asp-DPhe-Lys) with (64)Cu(2+). We show that the microreactor (made from polydimethylsiloxane and glass) can withstand 260 mCi of activity over 720 hours and retains only minimal amounts of (64)Cu(2+) (<5%) upon repeated use. A direct comparison between the radiolabeling yields obtained using the microreactor and conventional radiolabeling methods shows that improved mixing and heat transfer in the microreactor leads to higher yields for identical reaction conditions. Most importantly, by using small volumes (~10 µL) of concentrated solutions of reagents (>50 µM), yields of over 90% can be achieved in the microreactor when using a 1:1 stoichiometry of radiometal to BFC-BM. These high yields eliminate the need for use of excess amounts of often precious BM and obviate the need for a chromatographic purification process to remove unlabeled ligand. The results reported here demonstrate the potential of microreactor technology to improve the production of patient-tailored doses of radiometal-based radiopharmaceuticals in the clinic.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20941431     DOI: 10.1039/c0lc00162g

Source DB:  PubMed          Journal:  Lab Chip        ISSN: 1473-0189            Impact factor:   6.799


  8 in total

1.  Development of a microfluidic "click chip" incorporating an immobilized Cu(I) catalyst.

Authors:  Hairong Li; Joseph J Whittenberg; Haiying Zhou; David Ranganathan; Amit V Desai; Jan Koziol; Dexing Zeng; Paul J A Kenis; David E Reichert
Journal:  RSC Adv       Date:  2015-01-01       Impact factor: 3.361

2.  Cerenkov Luminescence Imaging in the Development and Production of Radiopharmaceuticals.

Authors:  R Michael van Dam; Arion F Chatziioannou
Journal:  Front Phys       Date:  2021-03-03

3.  Microfluidic radiolabeling of biomolecules with PET radiometals.

Authors:  Dexing Zeng; Amit V Desai; David Ranganathan; Tobias D Wheeler; Paul J A Kenis; David E Reichert
Journal:  Nucl Med Biol       Date:  2012-10-15       Impact factor: 2.408

4.  Fabrication of X-ray compatible microfluidic platforms for protein crystallization.

Authors:  Sudipto Guha; Sarah L Perry; Ashtamurthy S Pawate; Paul J A Kenis
Journal:  Sens Actuators B Chem       Date:  2012-11       Impact factor: 7.460

5.  New cross-bridged cyclam derivative CB-TE1K1P, an improved bifunctional chelator for copper radionuclides.

Authors:  Dexing Zeng; Qin Ouyang; Zhengxin Cai; Xiang-Qun Xie; Carolyn J Anderson
Journal:  Chem Commun (Camb)       Date:  2014-01-04       Impact factor: 6.222

6.  Triazine-based tool box for developing peptidic PET imaging probes: syntheses, microfluidic radiolabeling, and structure-activity evaluation.

Authors:  Hairong Li; Haiying Zhou; Stephanie Krieger; Jesse J Parry; Joseph J Whittenberg; Amit V Desai; Buck E Rogers; Paul J A Kenis; David E Reichert
Journal:  Bioconjug Chem       Date:  2014-04-04       Impact factor: 4.774

Review 7.  Microfluidics for synthesis of peptide-based PET tracers.

Authors:  Yang Liu; Mei Tian; Hong Zhang
Journal:  Biomed Res Int       Date:  2013-10-31       Impact factor: 3.411

8.  Development and implementation of ISAR, a new synthesis platform for radiopharmaceutical production.

Authors:  Christopher Frank; Georg Winter; Fredrik Rensei; Victor Samper; Allen F Brooks; Brian G Hockley; Bradford D Henderson; Christian Rensch; Peter J H Scott
Journal:  EJNMMI Radiopharm Chem       Date:  2019-09-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.